Conivaptan
(Vaprisol®): a nonpeptide antagonist of V1A & V2 vasopressin receptors. FDA approved for euvolemic and hypervolemic moderate-to-severe hyponatremia in hospitalized patients (NB: severe symptoms of seizures, coma, delirium…warrants aggressive treatment with hypertonic saline 1)).
1)
Ellison DH, Berl T. Clinical practice. The syndrome
of inappropriate antidiuresis. N Engl J Med. 2007;
356:2064–2072